Rate My Professor Arthi Kanthasamy

Kanthasamy's contributions extend to neuroinflammation, protein misfolding, and translational therapeutics, including small molecule inhibitors targeting PKCδ, Fyn kinase, and Kv1.3 channels, mitochondria-targeted antioxidants, and engineered L-DOPA-producing gut bacteria for Parkinson's disease. Key publications include 'PKC Delta Activation Promotes Endoplasmic Reticulum Stress (ERS) and NLR Family Pyrin Domain-Containing 3 (NLRP3) Inflammasome Activation Subsequent to α-Synuclein-Induced Microglial Activation: Involvement of Thioredoxin-Interacting Protein (TXNIP)/Thioredoxin (Trx) Redoxisome Pathway' (2021), 'Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Enhances Activation of STAT3/NLRC4 Inflammasome Signaling Axis through PKCδ in Astrocytes: Implications for Parkinson’s Disease' (2020), 'Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms' (2019), 'Histone hyperacetylation up-regulates protein kinase Cδ in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease' (2014), and 'Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration' (2016). Her research, supported by NIH, DOD, and the Michael J. Fox Foundation, holds implications for treating neuroinflammatory disorders.